SCOPE-II is a sponsor-initiated, current care randomized, controlled, non-inferiority trial evaluating safety and clinical efficacy of the Symetis ACURATE neo compared to the Medtronic Evolut R bioprosthesis in transfemoral transcatheter aortic valve implantation.
- Composite of all-cause mortality or stroke at 1 year.
- Clinical trial documentation,
- Set-up activities,
- eCRF / data-management,
- CoreLab activities,
- Clinical report
UK, Germany, France, Denmark, Spain and Italy.